41 related articles for article (PubMed ID: 2890147)
21. Acid secretory changes and early relapse following duodenal ulcer healing with ranitidine or sucralfate.
Marks IN; Johnston DA; Young GO
Am J Med; 1991 Aug; 91(2A):95S-101S. PubMed ID: 1882911
[TBL] [Abstract][Full Text] [Related]
22. H2-receptor antagonists: development and application.
Feldman S
N Engl Reg Allergy Proc; 1986; 7(4):362-6. PubMed ID: 2886903
[TBL] [Abstract][Full Text] [Related]
23. The efficacy, safety and dosage of sucralfate in ulcer therapy.
Marks IN
Scand J Gastroenterol Suppl; 1987; 140():33-8. PubMed ID: 3328283
[TBL] [Abstract][Full Text] [Related]
24. [Histamine H2-receptor antagonists as new anti-ulcer agents].
Takemoto T
Nihon Rinsho; 1984 Jan; 42(1):103-13. PubMed ID: 6143835
[No Abstract] [Full Text] [Related]
25. Drugs for the prevention of peptic ulcer recurrence.
Piper DW
Drugs; 1983 Nov; 26(5):439-53. PubMed ID: 6315333
[TBL] [Abstract][Full Text] [Related]
26. Treatment of duodenal ulcer.
Eliakim R; Rachmilewitz D
Rev Clin Basic Pharm; 1985; 5(3-4):215-33. PubMed ID: 2881325
[TBL] [Abstract][Full Text] [Related]
27. Omeprazole: a pharmacoeconomic evaluation of its use in duodenal ulcer and reflux oesophagitis.
Barradell LB; McTavish D
Pharmacoeconomics; 1993 Jun; 3(6):482-510. PubMed ID: 10146883
[TBL] [Abstract][Full Text] [Related]
28. Comparison of ranitidine and cimetidine ulcer maintenance therapy.
Kurata JH; Koch GG; Nogawa AN
J Clin Gastroenterol; 1987 Dec; 9(6):644-50. PubMed ID: 3327884
[TBL] [Abstract][Full Text] [Related]
29. [Prevention of duodenal ulcer recurrence. A new prospect].
Soulé JC
Presse Med; 1991 Mar; 20(10):465-70. PubMed ID: 1673786
[TBL] [Abstract][Full Text] [Related]
30. Safety profile of long-term H2-antagonist therapy.
Lewis JH
Aliment Pharmacol Ther; 1991; 5 Suppl 1():49-57. PubMed ID: 1679672
[TBL] [Abstract][Full Text] [Related]
31. The other option in peptic ulcer therapy.
Halter F
S Afr Med J; 1984 Jun; 65(25):996-1000. PubMed ID: 6374932
[TBL] [Abstract][Full Text] [Related]
32. Combination sucralfate and histamine2-antagonist therapy.
Gales MA; Steadman BK
Ann Pharmacother; 1994 May; 28(5):597-600. PubMed ID: 7915150
[No Abstract] [Full Text] [Related]
33. Medical and surgical prophylaxis for duodenal ulcer, the role of sucralfate.
Aärimaa M
Scand J Gastroenterol Suppl; 1987; 127():81-5. PubMed ID: 3303296
[TBL] [Abstract][Full Text] [Related]
34. Maintenance treatment with H2 receptor antagonists for duodenal ulcer disease: toward a rational use.
Kohn A; Annibale B; Delle Fave G; Levenstein S
Dig Dis; 1993; 11(4-5):228-38. PubMed ID: 7900939
[TBL] [Abstract][Full Text] [Related]
35. Clinical aspects of gastroduodenal ulcer recurrence: an overview.
Bynum TE
Scand J Gastroenterol Suppl; 1992; 191():1-3. PubMed ID: 1357739
[TBL] [Abstract][Full Text] [Related]
36. Pharmaco-economic considerations in the long-term management of peptic ulcer disease.
Ruszniewski P
Aliment Pharmacol Ther; 1993; 7 Suppl 2():41-8. PubMed ID: 8103375
[TBL] [Abstract][Full Text] [Related]
37. Duodenal ulcer. Who should have long-term maintenance therapy?
Zuckerman G
Postgrad Med; 1987 Oct; 82(5):52-3, 57-8, 60. PubMed ID: 2890147
[TBL] [Abstract][Full Text] [Related]
38. Treatment of duodenal ulcer with sucralfate.
Lam SK
Scand J Gastroenterol Suppl; 1991; 185():22-8. PubMed ID: 1683491
[TBL] [Abstract][Full Text] [Related]
39. Sucralfate maintenance therapy in duodenal ulcer disease. A review.
Bolin TD
Am J Med; 1989 Jun; 86(6A):148-51. PubMed ID: 2567571
[TBL] [Abstract][Full Text] [Related]
40. Prevention of duodenal ulcer recurrence.
Strum WB
Ann Intern Med; 1986 Nov; 105(5):757-61. PubMed ID: 2876669
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
